Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5 PSA/MUC1/Brachyury Vaccine in mCRPC
NCT03481816Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2018
- Primary completion
- Jan 2020
- Modality
- Gene Editing, Viral Vector Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of adenovirus PSA vaccine, ETBX-061 and ETBX-051 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Recommended Phase 2 Dose at 4 weeks. Started Jul 2018; status: completed.
02
Drugs
adenovirus PSA vaccineETBX-061ETBX-051
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03481816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03481816.